Prostate cancer is a clinically heterogeneous disease, with some men having indolent
disease that can safely be observed, while others have aggressive, lethal disease. Over the
past decade, researchers have begun to unravel some of the genomic heterogeneity that
contributes to these varying clinical phenotypes. Distinct molecular sub-classes of prostate
cancer have been identified, and the uniqueness of these sub-classes has been leveraged
to predict clinical outcomes, design novel biomarkers for prostate cancer diagnosis, and …